Yang Kan

Prof. Dr. Yang Kan

Intensive care unit, West China School of Medicine/West China Hospital of Sichuan University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in Biomaterials
Verified
Journal Article
Closed access
YKYang Kan
Yang Kan
YLYuanpei Li
Yuanpei Li
JLJuntao Luo
Juntao Luo
JLJoyce S. Lee
Joyce S. Lee
WXWenwu Xiao
Wenwu Xiao
KLKit S. Lam
Kit S. Lam

1 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
QFQiyi Feng
Qiyi Feng
YLYanping Liu
Yanping Liu
JHJian Huang
Jian Huang
KCKe Chen
Ke Chen
JHJinxing Huang
Jinxing Huang
YKYang Kan
Yang Kan
Iron oxide nanoparticles (IONPs) have been increasingly used in biomedical applications, but the comprehensive understanding of their interactions with biological systems is relatively limited. In this study, we systematically investigated the in vitro cell uptake, cytotoxicity, in vivo distribution, clearance and toxicity of commercially available and well-characterized IONPs with different sizes and coatings. Polyethylenimine (PEI)-coated IONPs exhibited significantly higher uptake than PEGylated ones in both macrophages and cancer cells, and caused severe cytotoxicity through multiple mechanisms such as ROS production and apoptosis. 10 nm PEGylated IONPs showed higher cellular uptake than 30 nm ones, and were slightly cytotoxic only at high concentrations. Interestingly, PEGylated IONPs but not PEI-coated IONPs were able to induce autophagy, which may play a protective role against the cytotoxicity of IONPs. Biodistribution studies demonstrated that all the IONPs tended to distribute in the liver and spleen, and the biodegradation and clearance of PEGylated IONPs in these tissues were relatively slow (>2 weeks). Among them, 10 nm PEGylated IONPs achieved the highest tumor uptake. No obvious toxicity was found for PEGylated IONPs in BALB/c mice, whereas PEI-coated IONPs exhibited dose-dependent lethal toxicity. Therefore, it is crucial to consider the size and coating properties of IONPs in their applications.

1 August 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
QXQiyue Xia
Qiyue Xia
JHJinxing Huang
Jinxing Huang
QFQiyi Feng
Qiyi Feng
XCXuanming Chen
Xuanming Chen
XLXinyi Liu
Xinyi Liu
YKYang Kan
Yang Kan
Background: Gold nanoparticles (AuNPs) have shown great promise in biomedical applications. However, the interaction of AuNPs with biological systems, its underlying mechanisms and influencing factors need to be further elucidated. Purpose: The aim of this study was to systematically investigate the effects of particle size on the uptake and cytotoxicity of AuNPs in normal cells and cancer cells as well as their biological distribution in vivo. Results: Our data demonstrated that the uptake of AuNPs increased in HepG2 cancer cells but decreased in L02 normal cells, with the increase of particle size (5-50 nm). In both cancer cells and normal cells, small (5 nm) AuNPs exhibited greater cytotoxicity than large ones (20 and 50 nm). Interestingly, 5 nm AuNPs induced both apoptosis and necrosis in HepG2 cells through the production of reactive oxygen species (ROS) and the activation of pro-caspase3, whereas it mainly induced necrosis in L02 cells through the overexpression of TLR2 and the release of IL-6 and IL-1a cytokines. Among them, 50 nm AuNPs showed the longest blood circulation and highest distribution in liver and spleen, and the treatment of 5 nm AuNPs but not 20 nm and 50 nm AuNPs resulted in the increase of neutrophils and slight hepatotoxicity in mice. Conclusion: Our results indicate that the particle size of AuNPs and target cell type are critical determinants of cellular uptake, cytotoxicity and underlying mechanisms, and biological distribution in vivo, which deserves careful consideration in the future biomedical applications.

31 May 2022 in Advanced Materials
Verified
Journal Article
Closed access
JHJinxing Huang
Jinxing Huang
CZCheng Zhuang
Cheng Zhuang
JCJie Chen
Jie Chen
XCXuanming Chen
Xuanming Chen
XLXiaojie Li
Xiaojie Li
WLWeimin Li
Weimin Li

1 October 2011 in Journal of Controlled Release
Verified
Journal Article
Closed access
YKYang Kan
Yang Kan
JLJuntao Luo
Juntao Luo
YLYuanpei Li
Yuanpei Li
JLJoyce S. Lee
Joyce S. Lee
GFGabriel Fung
Gabriel Fung
KLKit S. Lam
Kit S. Lam

22 August 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XLXinyi Liu
Xinyi Liu
CXChunxiu Xiao
Chunxiu Xiao
YKYang Kan
Yang Kan
Nanotechnology offers the possibility of revolutionizing cancer theranostics in the new era of precision oncology. Extracellular vesicles (EVs)-like biomimetic nanoparticles (EBPs) have recently emerged as a promising platform for targeted cancer drug delivery. Compared with conventional synthetic vehicles, EBPs have several advantages, such as lower immunogenicity, longer circulation time, and better targeting capability. Studies on EBPs as cancer therapeutics are rapidly progressing from in vitro experiments to in vivo animal models and early-stage clinical trials. Here, we describe engineering strategies to further improve EBPs as effective anticancer drug carriers, including genetic manipulation of original cells, fusion with synthetic nanomaterials, and direct modification of EVs. These engineering approaches can improve the anticancer performance of EBPs, especially in terms of tumor targeting effectiveness, stealth property, drug loading capacity, and integration with other therapeutic modalities. Finally, the current obstacles and future perspectives of engineered EBPs as the next-generation delivery platform for anticancer drugs are discussed.